CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 8 enrolled
Drug / intervention
Copanlisib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03877055
NCT03877055Phase 2Completed
CompareCT.gov

Phase I/II Clinical Trial of Copanlisib and Ibrutinib in Mantle Cell Lymphoma

Memorial Sloan Kettering Cancer Center·interventional·Posted Mar 15, 2019·Updated Dec 14, 2022

In Brief

A Phase 2 clinical trial evaluating Copanlisib and Ibrutinib for Mantle Cell Lymphoma (MCL). Completed, enrolled 8 participants across 6 sites.

Detailed Summary

The purpose of this study is to test the safety and any good and bad side effects of combining 2 study drugs, copanlisib and ibrutinib. This combination of drugs could shrink your Mantle Cell Lymphoma (MCL), but it could also cause side effects. Both these drugs have been given to people before, but this is the first time that they are being given together.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMantle Cell Lymphoma (MCL)
CountriesUnited States
CollaboratorsBayer

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMar 15, 2019
Enrollment StartMar 13, 2019
Primary CompletionOct 7, 2022
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 7.3 years ago

Interventions

Copanlisibdrug

Treatment will be with intravenous copanlisib on days 1, 8, 15 of 28 day cycles.

Ibrutinibdrug

Oral ibrutinib daily in 28 day cycles. A cycle is defined as 28 days of therapy.